Eyecare

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.

The annual dilated retinal exam, a unique tool which uses drops to dilate the pupil, is not just about eye health. It offers a comprehensive view of a member's overall well-being, potentially identifying serious health issues at an early stage.

The prefilled syringe of Vabysmo will become available in the coming months. It treats age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion.

The active ingredient in Ozempic and Wegovy is linked to nonarteritic anterior ischemic optic neuropathy (NAION), the second most common form of optic neuropathy. This is apparently the first study to link semaglutide to the eye condition.

Lack of standardization has obscured complication rates in clinical trials, say a team of researchers. In results reported in the journal Ophthalmology earlier month, they list 67 ocular complications that experts agreed upon using a Delphi process,

Researchers say their findings of increased prevalence argue for screening for diabetic retinopathy in young adults.

In a study in mice, researchers found that the COVID-19 virus can infect the retina even when the virus doesn’t enter through the eyes.

Some large randomized trials have suggested that taking low doses of aspirin on a daily basis would be an easy, inexpensive way of lowering the risk of getting age-related macular degeneration. Not so a well-designed, placebo-controlled study of septuagenarians conducted in Australia.

Yesafili and Opuviz are approved to treat patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

Researchers find a mismatch between demographics of the neighborhoods where the FQHCs with vision care are located and those using the vision services.

Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.

Results published in the journal Ophthalmology find no risk reduction from daily one-gram capsules of omega-3 fatty acids.

Experts say ordinary sunglasses aren't protective enough for viewers of the solar eclipse on Monday. You need those certified eclipse glasses. Ten-packs were selling on Amazon today for $12.99.

The AI system correctly identified all of the severe cases and accurately detected 80% of the cases with more-than-mild retinopathy of prematurity in a real-world population.

Vision symptoms resolved within a month, the specialists said in their report in JAMA Ophthalmology, but they say that retina specialists need to be aware that ths side effect from Vabysmo (faricimab) is more common that data from clinical trials would indicate.

iDose TR was approved to reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It has a wholesale acquisition cost of $13,950 per dose/implant.

Researchers have identified an association between cataract surgery and a lower risk of cognitive decline and dementia.

Johns Hopkins researchers investigated how home environments may affect physical activity.

Glaucoma is a leading cause of blindness, and African Americans and other minorities have a higher risk for the disease.

Outlook Therapeutics plans to begin a study in the first quarter of 2024 to address the issues identified in a FDA complete response letter. If approved, Lytenava would be the only bevacizumab product to specifically treat age-related macular degeneration.

IDose TR will be available in first quarter of 2024 with a wholesale acquisition cost of $13,950 per dose/implant.

A California retinal specialist argues in a JAMA Ophthalmology viewpoint article that an independent panel of retinal specialists and statisticians should assess the data from clinical trials of Syfovre (pegcetacoplan) because of the lack of a complete FDA scientific analysis of the drug and of peer-reviewed publication.

The survey highlights a growing willingness among employees to pay for premium lens options and a focus on early diagnosis of eye conditions, aligning with the broader trend of holistic well-being.

Regulators indicated that an additional trial would be needed to assess the efficacy of reproxalap to treat patients with dry eye. Aldeyra has submitted to the FDA a Special Protocol Assessment for the new trial.

Beovu led to greater improvement in retinal thickness and reduction of retinal fluid in patients with diabetic macular edema, a secondary endpoint in this head-to-head trial.

The announcement has triggered a wave of concerns among users of eye-care products, particularly in those designed to alleviate dry and irritated eyes.

Byooviz was approved as the first biosimilar to Lucentis and launched with a list price of $1,130 per single-use vial.

The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.

The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.